A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

Audit and Risk Committee ToR March 2026

Description
Audit and Risk Committee Terms of Reference Version: 8 Date Issued: Review Date: Document Type: 10 March 2026 January 2027 Committee
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2026-Trust-documents/Audit-and-Risk-Committee-ToR-March-2026.pdf

Audit and Risk Committee ToR March 2025

Description
Audit and Risk Committee Terms of Reference Version: 7 Date Issued: Review Date: Document Type: 11 March 2025 January 2026 Committee
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2025-Trust-documents/Audit-and-Risk-Committee-ToR-March-2025.pdf

Glofitamab-Obinutuzumab

Description
Chemotherapy Protocol LYMPHOMA GLOFITAMAB-OBINUTUZUMAB Regimen • Lymphoma-Glofitamab-Obinutuzumab Indication • Treatment of adult patients with relapsed or refractory diffuse large B
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Glofitamab-Obinutuzumab.pdf

Tips on a speedier recovery after an operation - patient information

Description
This factsheet explains what to expect after having an operation and gives tips and exercises to help speed up your recovery
Url
/Media/UHS-website-2019/Patientinformation/Respiratory/Tips-on-a-speedier-recovery-after-an-operation-751-PIL.pdf

Audit and Risk Committee ToR Jan 2023

Description
Audit and Risk Committee Terms of Reference Version: 5 Date Issued: Review Date: Document Type: 31 January 2023 January 2024 Committee
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2023-Trust-documents/Audit-and-Risk-Committee-ToR-Jan-2023.pdf

Papers Trust Board 28 March 2019

Description
Agenda Group Name: Date of Meeting: Venue: Time: Apologies to: Trust Board – Open Session 28 March 2019 Conference Room, Heartbeat Education
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2019/Papers-Trust-Board-28-March-2019.pdf

Audit and Risk Committee ToR Jan 2022

Description
Audit and Risk Committee Terms of Reference Date Issued: 27 January 2022 Review Date: January 2023 Document Type: Committee Terms of
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Audit-and-Risk-Committee-ToR-Jan-2022.pdf

ObinutuzumabVenetoclax LowRisk

Description
Chemotherapy Protocol Chronic Lymphocytic Leukaemia Obinutuzumab-Venetoclax (Low Risk) Regimen • CLL – Obinutuzumab-Venetoclax (Low Risk) Indication • Chronic lymphatic leukaemia (CLL) or
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/ObinutuzumabVenetoclax-LowRisk.pdf

UHS AR 21-22 Quality Account

Description
QUALITY ACCOUNT 2021/22 Part 1: QStaUteAmeLnItToYn qAuaClitCy fOroUm NtheTchief executive 2021/22 1.1 Chief executive’s statement and welcome
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/UHS-AR-21-22-Quality-Account.pdf

Chlorambucil_2_Obinutuzumab

Description
Chemotherapy Protocol Chronic Lymphocytic Leukaemia Chlorambucil (2 day)-Obinutuzumab (6 cycles) Regimen • CLL – Chlorambucil (2 day)-Obinutuzumab Indication • The first line
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Chlorambucil-2-Obinutuzumab.pdf
41 to 50 of 1000
Previous … 3 4 5 6 7 … Next